- Home
- JYD vs LEXX Comparison
JYD vs LEXX Comparison
Compare JYD & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JYD
- LEXX
- Stock Information
- Founded
- JYD 2001
- LEXX 2004
- Country
- JYD China
- LEXX Canada
- Employees
- JYD N/A
- LEXX N/A
- Industry
- JYD Oil Refining/Marketing
- LEXX Biotechnology: Pharmaceutical Preparations
- Sector
- JYD Consumer Discretionary
- LEXX Health Care
- Exchange
- JYD Nasdaq
- LEXX Nasdaq
- Market Cap
- JYD 18.9M
- LEXX 16.5M
- IPO Year
- JYD 2023
- LEXX N/A
- Fundamental
- Price
- JYD $0.14
- LEXX $1.21
- Analyst Decision
- JYD
- LEXX Strong Buy
- Analyst Count
- JYD 0
- LEXX 1
- Target Price
- JYD N/A
- LEXX $4.00
- AVG Volume (30 Days)
- JYD 940.9K
- LEXX 199.9K
- Earning Date
- JYD 10-24-2025
- LEXX 07-14-2025
- Dividend Yield
- JYD N/A
- LEXX N/A
- EPS Growth
- JYD N/A
- LEXX N/A
- EPS
- JYD N/A
- LEXX N/A
- Revenue
- JYD $77,444,271.00
- LEXX $615,923.00
- Revenue This Year
- JYD N/A
- LEXX $46.98
- Revenue Next Year
- JYD N/A
- LEXX $17.26
- P/E Ratio
- JYD N/A
- LEXX N/A
- Revenue Growth
- JYD 13.54
- LEXX 49.85
- 52 Week Low
- JYD $0.09
- LEXX $0.77
- 52 Week High
- JYD $8.00
- LEXX $3.41
- Technical
- Relative Strength Index (RSI)
- JYD 36.82
- LEXX 60.29
- Support Level
- JYD $0.13
- LEXX $0.98
- Resistance Level
- JYD $0.16
- LEXX $1.34
- Average True Range (ATR)
- JYD 0.01
- LEXX 0.11
- MACD
- JYD -0.00
- LEXX 0.04
- Stochastic Oscillator
- JYD 34.21
- LEXX 55.77
About JYD Jayud Global Logistics Limited
Jayud Global Logistics Ltd is an end-to-end supply chain solution provider in China, with a focus on providing cross-border logistics services. The company offers freight forwarding services, supply chain management, and other value-added services.
About LEXX Lexaria Bioscience Corp.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.